Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets.

Mauvais FX, Diana J, van Endert P.

F1000Res. 2016 Apr 22;5. pii: F1000 Faculty Rev-728. doi: 10.12688/f1000research.7411.1. eCollection 2016. Review.

2.

Inducing and Administering Tregs to Treat Human Disease.

Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC.

Front Immunol. 2016 Jan 22;6:654. doi: 10.3389/fimmu.2015.00654. eCollection 2015. Review.

3.

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.

Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K, Ehlers MR, McNamara JG, Harris KM, Kanaparthi S, Phippard D, Herold KC.

Eur J Immunol. 2016 Jan;46(1):230-41. doi: 10.1002/eji.201545708. Epub 2015 Dec 14.

4.

Immune intervention for type 1 diabetes, 2013-2014.

Skyler JS.

Diabetes Technol Ther. 2015 Feb;17 Suppl 1:S80-7. doi: 10.1089/dia.2015.1510. No abstract available.

5.

Regulatory T cells control diabetes without compromising acute anti-viral defense.

Baca Jones C, Pagni PP, Fousteri G, Sachithanantham S, Dave A, Rodriguez-Calvo T, Miller J, von Herrath M.

Clin Immunol. 2014 Aug;153(2):298-307. doi: 10.1016/j.clim.2014.05.006. Epub 2014 May 22.

6.

The compelling case for anti-CD3 in type 1 diabetes.

Skyler JS.

Diabetes. 2013 Nov;62(11):3656-7. doi: 10.2337/db13-1157. No abstract available.

7.

CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

Chatenoud L, Waldmann H.

Rev Diabet Stud. 2012 Winter;9(4):372-81. doi: 10.1900/RDS.2012.9.372. Epub 2012 Dec 28. Review.

8.

Clinical potential of antigen-specific therapies in type 1 diabetes.

Coppieters KT, Sehested Hansen B, von Herrath MG.

Rev Diabet Stud. 2012 Winter;9(4):328-37. doi: 10.1900/RDS.2012.9.328. Epub 2012 Dec 28. Review.

9.

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J; Protégé Trial Investigators.

Diabetes. 2013 Nov;62(11):3901-8. doi: 10.2337/db13-0236. Epub 2013 Jun 25.

10.

Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.

Robert S, Korf H, Gysemans C, Mathieu C.

Islets. 2013 Mar-Apr;5(2):53-66. doi: 10.4161/isl.24785. Epub 2013 Mar 1. Review.

11.

Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes.

Hu C, Ding H, Zhang X, Wong FS, Wen L.

Diabetes. 2013 Aug;62(8):2849-58. doi: 10.2337/db12-1175. Epub 2013 Feb 27.

12.

Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.

Staeva TP, Chatenoud L, Insel R, Atkinson MA.

Diabetes. 2013 Jan;62(1):9-17. doi: 10.2337/db12-0562. Review. No abstract available.

13.

Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine.

Orban T, Kis JT.

Ther Adv Endocrinol Metab. 2011 Feb;2(1):9-16. doi: 10.1177/2042018810390546.

14.

The use of peptide-major-histocompatibility-complex multimers in type 1 diabetes mellitus.

Gojanovich GS, Murray SL, Buntzman AS, Young EF, Vincent BG, Hess PR.

J Diabetes Sci Technol. 2012 May 1;6(3):515-24. Review.

15.

Making the most of major histocompatibility complex molecule multimers: applications in type 1 diabetes.

Gojanovich GS, Hess PR.

Clin Dev Immunol. 2012;2012:380289. doi: 10.1155/2012/380289. Epub 2012 May 28. Review.

16.

Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, Dotta F, Rottiers P, Gysemans C, Mathieu C.

J Clin Invest. 2012 May;122(5):1717-25. doi: 10.1172/JCI60530. Epub 2012 Apr 9.

17.

Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.

Mamchak AA, Manenkova Y, Leconet W, Zheng Y, Chan JR, Stokes CL, Shoda LK, von Herrath M, Bresson D.

Diabetes. 2012 Jun;61(6):1490-9. doi: 10.2337/db11-1304. Epub 2012 Feb 23.

18.

Immune intervention in type 1 diabetes.

Michels AW, Eisenbarth GS.

Semin Immunol. 2011 Jun;23(3):214-9. doi: 10.1016/j.smim.2011.07.003. Epub 2011 Aug 17. Review.

19.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators.

Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.

20.

Humanizing animal models: a key to autoimmune diabetes treatment.

Bresson D, von Herrath M.

Sci Transl Med. 2011 Feb 2;3(68):68ps4. doi: 10.1126/scitranslmed.3002102.

Supplemental Content

Support Center